Nova Patents
PL342183A1

Azolo-triazines and-pyrimidines

Abstract

Corticotropin releasing factor (CRF) antagonists for formula (I) or (II) and their use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.

Term

Term ended

Projected expiry passed 28 January 2019, 7.7 years ago.

  1. Priority
  2. Filed
  3. Published
  4. Projected expiry
  5. Today

154 members in 35 offices

This recordMember, by publication datePriority claim25 more offices are in the list below

Priority claims16

Priority claims
DocumentOfficeKindDate
1473498United States of AmericaA
1473498United States of AmericaA
1500198United States of AmericaA
1500198United States of AmericaA
1500298United States of AmericaA
1500298United States of AmericaA
9901824United States of AmericaW
9901824United States of AmericaW
14734–––
15001–––
15002–––
US19980014734–––
US19980015001–––
US19980015002–––
US9901824–––
WO1999US01824–––

Members154

Family members, oldest first
DocumentOfficeKind
AU6536880AAustraliaA
EP0033222A2European Patent Office (EPO)A2
EP0033222A3European Patent Office (EPO)A3
JPS56106659AJapanA
ES498733A0SpainA0
ES8204297A1SpainA1
DD157076A5German Democratic Republic (until 1990)A5
US4366061AUnited States of AmericaA
AU527275B2AustraliaB2
CA1167388ACanadaA
EP0033222B1European Patent Office (EPO)B1
DE3167359D1GermanyD1
EP0033222B2European Patent Office (EPO)B2
CA2259583A1CanadaA1
CA2532925A1CanadaA1
WO9803510A1World Intellectual Property Organization (WIPO)A1
AU3894297AAustraliaA
HRP970413A2CroatiaA2
NO990264D0NorwayD0
ZA976603BSouth AfricaB
NO990264LNorwayL
EP0915880A1European Patent Office (EPO)A1
LV12292ALatviaA
PL331523A1PolandA1
CA2314613A1CanadaA1
CA2614603A1CanadaA1
WO9938868A1World Intellectual Property Organization (WIPO)A1
CN1225637AChinaA
AU2478799AAustraliaA
EE9900019AEstoniaA
BR9710544ABrazilA
EA199900158A1Eurasian Patent Organization (EAPO)A1
IL127871A0IsraelA0
IL127871D0IsraelD0
SI9720045ASloveniaA
CZ18499A3CzechiaA3
LV12292BLatviaB
AR007994A1ArgentinaA1
LT99008ALithuaniaA
US6060478AUnited States of AmericaA
LT4680BLithuaniaB
NZ333777ANew ZealandA
US6124289AUnited States of AmericaA
US6136809AUnited States of AmericaA
EP1049699A1European Patent Office (EPO)A1
KR20000068010ARepublic of KoreaA
BR9908206ABrazilA
US6191131B1United States of AmericaB1
CN1289335AChinaA
KR20010040426ARepublic of KoreaA
PL342183A1This recordPolandA1
IL137019A0IsraelA0
IL137019D0IsraelD0
US6313124B1United States of AmericaB1
HU0102187A2HungaryA2
HUP0102187A2HungaryA2
CN1327793AChinaA
JP2002501922AJapanA
US6358950B1United States of AmericaB1
AU2323602AAustraliaA
JP2002513382AJapanA
AU747708B2AustraliaB2
AU748818B2AustraliaB2
IL150163A0IsraelA0
IL150163D0IsraelD0
HU0102187A3HungaryA3
HUP0102187A3HungaryA3
CN1388126AChinaA
US2003008885A1United States of AmericaA1
TW520372BTaiwan Province of ChinaB
CN1104432CChinaC
TW542827BTaiwan Province of ChinaB
NZ505079ANew ZealandA
EP1344779A1European Patent Office (EPO)A1
HK1052693AHong Kong, ChinaA
HK1052693A1Hong Kong, ChinaA1
NO315610B1NorwayB1
NO315610B3NorwayB3
TW200304916ATaiwan Province of ChinaA
NZ524842ANew ZealandA
AU748818CAustraliaC
CN1137123CChinaC
EA200301042A1Eurasian Patent Organization (EAPO)A1
EP1049699B1European Patent Office (EPO)B1
EA004403B1Eurasian Patent Organization (EAPO)B1
AU773039B2AustraliaB2
AT264860TAustriaT
ATE264860T1AustriaT1
DE69916578D1GermanyD1
EE04316B1EstoniaB1
DK1049699T3DenmarkT3
HK1060348AHong Kong, ChinaA
HK1060348A1Hong Kong, ChinaA1
PT1049699EPortugalE
SI1049699T1SloveniaT1
CN1542010AChinaA
ES2218991T3SpainT3
DE69916578T2GermanyT2
SK9799A3SlovakiaA3
JP2005097257AJapanA
Showing 100 of 154